Benitec Biopharma (NASDAQ:BNTC – Get Free Report) and Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.
Insider and Institutional Ownership
52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 4.8% of Benitec Biopharma shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Benitec Biopharma and Voyager Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Benitec Biopharma | 1 | 2 | 6 | 0 | 2.56 |
| Voyager Therapeutics | 1 | 0 | 2 | 1 | 2.75 |
Risk & Volatility
Benitec Biopharma has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.
Profitability
This table compares Benitec Biopharma and Voyager Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Benitec Biopharma | N/A | -34.82% | -34.11% |
| Voyager Therapeutics | -319.61% | -55.97% | -43.12% |
Valuation and Earnings
This table compares Benitec Biopharma and Voyager Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Benitec Biopharma | N/A | N/A | -$37.92 million | ($1.14) | -10.66 |
| Voyager Therapeutics | $36.49 million | 6.16 | -$119.72 million | ($1.97) | -1.89 |
Benitec Biopharma has higher earnings, but lower revenue than Voyager Therapeutics. Benitec Biopharma is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.
About Benitec Biopharma
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
About Voyager Therapeutics
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
